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Abstract 
Type 2 diabetes mellitus (T2DM) is the most common form of human diabetes, 
accounting for approximately 90% of cases and often coexists with obesity. Elevated 
triglyceride levels and small dense low density lipoprotein particles and reduced high 
density lipoprotein cholesterol constitute diabetic dyslipidemia.  Diabetic patients often 
develop hypertriglyceridemia (HTG) at the early stage of the disease, before the onset of 
overt hyperglycemia (diabetes).  It is well-established that genetic factors significantly 
influence the onset of HTG, yet no susceptibility genes for common forms of HTG have 
been identified in human populations to date. 
TALLYHO/JngJ (TH) mice are a newly established inbred polygenic model for 
obesity and T2DM.  These mice are characterized by insulin resistance, hyperinsulinemia, 
diabetes (males), obesity, and dyslipidemia.  TH male mice rapidly develop HTG at a 
very young age before the onset of overt diabetes, and this HTG is accompanied by 
hyperinsulinemia, and precedes glucose intolerance.  Accordingly, we hypothesize that 
the HTG may become a strong risk factor for overt diabetes in these mice and TH allelic 
differences at the underlying genetic susceptibility loci confer predisposition to HTG in 
TH mice.  In an attempt to test these hypotheses, the aim of this study is to establish the 
genomic location(s) linked to the HTG in TH mice. In order to achieve this aim, we 
generated F2 mice from an intercross of F1[C57BL/6J (B6) x TH] mice.  The F2 mice 
were then phenotyped for HTG and related traits including hypercholemia, 
hyperglycemia, and obesity.  F2 mice were also genotyped with simple sequence repeat 
markers over the entire genome.  Statistical analysis to detect significant loci that co-
segregate with the traits was conducted using quantitative trait loci (QTLs) mapping. 
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We found significant QTLs linked to HTG on chromosomes 1 and 8.  
Chromosome 1 QTL was also associated with hypercholesterolemia.  A significant QTL 
responsible for fat pad weights was detected on chromosome 1 located proximal to the 
HTG QTL.  A QTL on chromosome 4 was significantly linked to hyperglycemia.  For all 
these traits, mice homozygous for TH alleles exhibited higher values than mice 
heterozygous or homozygous for B6 alleles. 
In summary, our genetic study revealed a complex pattern of inheritance and 
mapped significant QTLs for HTG and related traits in TH mice.  Identifying the genes 
for these QTLs will enhance our understanding of diabetic HTG, and provide new targets 
to prevent it. 
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Chapter I: Introduction 
Type 2 diabetes mellitus (T2DM) is a common disease found in 3 to 5% of 
Western populations (1).  T2DM is a chronic and progressive disease characterized by 
insulin resistance and pancreatic beta cell failure.  Three abnormalities cause 
hyperglycemia in T2DM: impaired insulin secretion, increased hepatic glucose 
production, and decreased insulin-stimulated uptake of glucose in peripheral tissues (2).  
Cardiovascular disease (CVD), particularly coronary heart disease (CHD), is a major 
complication of this disease, and over 50% of T2DM patients die of CHD (1).  CHD, 
sudden death, and myocardial infarction are at least twice as high in patients with T2DM 
than in non diabetic subjects (3).   
T2DM patients are at increased risk for CVD already at diagnosis of diabetes. 
T2DM is a major cardiovascular risk factor in addition to elevated cholesterol and blood 
pressure, smoking, low HDL cholesterol and aging (4). A high proportion of patients with 
T2DM die within 1 year after an acute myocardial infarction, and a considerable number 
of patients die even before they reach the hospital (5).  Hyperglycemia was believed to 
cause diabetic complications.  Poor glycemic control is a strong risk factor for 
microvascular complications but its significance with respect to CVD is quite limited.  
Therefore, other risk factors for microangiopathy have to be considered.  Dyslipidemia is 
very common in patients with T2DM and it significantly contributes to the risk of CVD 
(6). 
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The development of T2DM is controlled by the interaction of multiple genetic 
and environmental factors (7).  Many candidate genes for  insulin resistance and β-cell 
biology have been studied and a few of them are associated with T2DM (8).  Genetic 
influences have been difficult to elucidate and determination of genes involved has not 
been easily achieved in humans (9).   Analysis of diabetes genes in rodents offers several 
advantages over the same studies in humans: A large number of animals can be bred, and 
both environmental influences and genetic heterogeneity can be controlled (10).  In 
addition, the possibility of creating similar genetic lesions in mice of different 
background can be used to identify important modifiers of disease genes, and new mouse 
models of diabetes can be created by gene insertions or targeted gene disruptions (11). 
TALLYHO/JngJ (TH) mouse strain is a polygenic model for T2DM with 
obesity.  TH mice are characterized by insulin resistance, hyperinsulinemia, 
hyperglycemia (males), obesity, and dyslipidemia associated with increased triglyceride, 
free fatty acid and cholesterol levels.  In previous studies from our laboratory, we 
demonstrated that male TH mice rapidly develop hypertriglyceridemia (HTG) at a young 
age before the onset of overt diabetes.  The objective of this study is to identify the 
underlying genetic susceptibility loci responsible for HTG in TH mice.  This study will 
enhance our understanding of diabetic HTG and provide new therapeutic targets for 
T2DM and dyslipidemia.  
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Chapter II: Literature review 
1. Obesity and Type 2 Diabetes Mellitus 
About of 65% of American adults are either overweight or obese (the Centers for 
Disease Control and Prevention; CDC) and the number of overweight and obese 
Americans continues to rise. Between NHANES (The National Health and Nutrition 
Examination Surveys, a series of surveys conducted periodically by the U.S. Department 
of Health and Human Services agencies) II (1976-1980) and NHANES 1999-2002, the 
percentage of obese adults nearly doubled (12). 
Obesity increases the risk of T2DM, heart disease, dyslipidemia, arthritis, 
gallstone formation, and certain cancer, including cancers of the breast, colon, uterus, 
pancreas, and kidney (13).  According to Colditz’s study in 1995, obese women are 7 to 
13 times more likely than woman of normal weight to develop T2DM (13,14).  Even a 
modest weight gain of 5 to 7 kg (11 to 15 lbs.) increases the risk of diabetes by 50%, 
while losing as little as 5kg (11 lbs.) reduces the risk by the same amount (14).  
 As the prevalence of obesity increases, the world faces a epidemic problem of 
T2DM (3).  According to International Diabetes Federation (IDF) the number of diabetic 
adults between 20 to 79 years at age will increase by around 70% in the next 20 years, 
from 194 million in 2003 to 330 million in 2025 (http://www.eatlas.idf.org/).  T2DM 
causes blindness (15), end-stage renal disease (16), and non traumatic loss of limb (17).  
Cardiovascular disease (CVD) causes the most serious fatal disease by T2DM, and 
T2DM patients have two to four times greater cardiovascular morbidity than that of non-
diabetic people (18).  Diabetic men have 2-3 and diabetic women have 3-5 times the 
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chance to have CVD compared with the non-diabetic population (19). 
The intra-abdominal fat depot or central subcutaneous fat depot is considered a 
risk factor for reduction in insulin sensitivity (20).  Obese people whose fat is stored in 
visceral adipose depots suffer more adverse metabolic consequences than those with fat 
stored predominantly in subcutaneous sites.  Excess abdominal fat mass is associated 
with an increased release of non-esterified free fatty acids (FFA) that may trigger a 
reduction in insulin sensitivity at both the hepatic and the muscular levels (21).  
In the liver, this results in an increased glucose output (essentially due to 
enhanced gluconeogenesis) and increased VLDL production, while in the skeletal muscle, 
there is a reduction in glucose oxidation and glucose storage as glycogen (22). 
Insulin-resistant obese patients suffer from impaired glucose tolerance, 
dyslipidemia and arterial hypertension, all factors which increase the risk of CVD.  
Interestingly, ectopic fat accumulation in insulin-sensitive tissues may be associated with 
insulin resistance independent of overall obesity (23). 
   T2DM occurs as a late phenomenon in obese subjects and is preceded by years of 
normal glucose tolerance or impaired glucose tolerance (IGT) as suggested by several 
cross-sectional studies (24).  The progression from IGT to diabetes occurs when the beta 
cell becomes unable to maintain its previously high rate of insulin secretion in response 
to glucose (25).  During the early years of obesity, subjects are normoglycemic but 
hyperinsulinemic then progressively become hyperglycemic when hyperinsulinemia is 
not maintained (26).  
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2. Pathogenesis of Type 2 Diabetes Mellitus 
T2DM develops when the body doesn’t make enough insulin or doesn’t 
efficiently use the insulin it makes (27).  Insulin resistance is characterized by defective 
glucose uptake by muscle and adipose tissue (28).  The primary abnormality in most 
cases of T2DM is insulin resistance (29).  The initial stage of insulin resistance, pre-
diabetic stage, is influenced by genetic factors and environmental factors with changes in 
insulin levels, and lipids (Figure 1).  These changes are followed by cardiovascular 
complications in genetically susceptible people, before the onset of diabetes (27).  The 
onset of diabetes is characterized by hyperglycemia and hyperinsulinemia, followed by 
rising fasting plasma glucose or rising peak plasma glucose challenge, levels in response 
to an oral glucose with hyperglycemia leading to a diagnosis of T2DM.   
T2DM is defined as a fasting blood glucose of ≥126 mg/dl. “Pre-diabetes” is a 
condition in which blood glucose levels are higher than normal and precedes diabetes.   
People with pre-diabetes are at increased risk for developing T2DM and have one of 
these conditions: impaired fasting glucose (100 ~ 125 mg/dl) and impaired glucose 
tolerance (fasting glucose less than 126 mg/dl and a glucose level between 140 and 199 
mg/dl two hours after taking an oral glucose tolerance test).   
Since insulin is produced by pancreatic β-cells, dysfunction of these cell is a 
critical factor in the pathogenesis of T2DM (30).  When insulin action decreases with 
increased obesity, concentrations of blood glucose as fasting and 2 hours after glucose 
load will increase slowly (31,32). 
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Figure 1. Model of the progressive pathogenesis of type 2 diabetes mellitus. 
In most individuals there is a slow progression from normal to impaired glucose tolerance 
(IGT) to diabetes. This depends on interactions between genetic and environmental 
factors that act on both initiation and progression of the disease (33). 
 
  
Insulin: Insulin is secreted from β-cells in the pancreas and controls blood 
glucose. In normal conditions, insulin inhibits glucose production from the liver and 
stimulates the uptake of glucose into peripheral tissues to use as energy (34).  In 
addition, insulin regulates in lipid metabolism.  In adipose tissue, insulin stimulates FFA 
uptake, esterification, and storages into increased TG via lipogenesis.  Insulin promotes 
FFA uptake into the adipose tissue by stimulation of lipoprotein lipase (LPL) which 
hydrolyzes lipoprotein triglyceride (TG). Also, insulin promotes TG synthesis from 
glucose.  However, insulin inhibits hormone-sensitive lipase (HSL) which is the 
principal regulator of FFA release from adipose tissue, and prevents lipolysis of TG in 
adipose tissue.  
Initiation factors 
Insulin resistance genes
Insulin secretion genes 
Beta cell genes 
Obesity genes 
Progression factors 
Obesity 
Beta cell failure 
Diet and environment
Activity and age 
T2DMNormal IGT
Failing insulin secretion  
Glucose desensitization of beta cell 
Decreased insulin and glucose sensitivity
Increased insulin secretion
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Insulin signaling: Insulin acts through a subfamily of receptor tyrosine kinases; 
the insulin receptor (IR) and insulin-like growth factor-I receptor (IGF-IR).  They 
catalyze the phosphorylation of several intercellular substrates, including the insulin 
receptor substrate (IRS) protein, growth factor receptor bound protein 2-associated 
protein 1 (GAB-1), src homology 2 domain-containing transforming protein C (Shc), 
adaptor protein with pleckstrin homology and src (APS), and signal-regulatory proteins 
(SIRPS) (35,36).  The signaling cascades of these two receptors are quite similar.  The IR 
undergoes autophosphorylation and affects signal transduction primarily by activating 
two pathways, the IRS - phosphoinositide-3 kinase (PI3K) - Akt pathway and the Ras – 
Raf – Mitogen Activated Protein Kinase (MAPK) pathway.  The c-Jun N-terminal kinase 
(JNK) and p38 MAPK pathways are also activated by insulin.  The IGF-IR activates 
these same pathways in a similar fashion.  The IR primarily regulates fuel metabolism 
and the IGF-IR modulates cell growth and survival (37). 
Insulin-sensitive tissues such as liver, fat, and muscle are involved in regulating 
whole body fuel metabolism.  Insulin’s effect is controlled by the IRS-PI3K-Akt pathway.  
In fat and muscle, activation of this pathway leads to translocation of intracellular glucose 
transporter 4 (GLUT4), to the surface membrane, resulting in enhanced glucose uptake 
(38).  In addition, it has been reported that GLUT4 gene expression in fat and muscle is 
reduced in T2DM and this leads to reduced uptake of glucose from blood (39).  In liver, 
insulin acts to down regulate glucose production by inhibiting the expression of 
gluconeogenic genes (40).   
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3. Diabetic Dyslipidemia 
Dyslipidemia is commonly found in patients with T2DM (41).  Dyslipidemia 
precedes onset of T2DM and frequently impaired glucose tolerance (IGT) by years, 
indicating that disturbance of lipid metabolism may be the primary event in the 
development of T2DM (42) (Table 1).  In recent study, lean insulin resistant offspring of 
patients with T2DM were shown to have increased intrameyocellular lipid contents, 
which was attributable to a reduction of mitochondrial phophorylation (43).   Increased 
liver fat content and resulting non-alcoholic fatty liver or non-alcoholic steatohepatitis are 
also very commonly found in T2DM subjects with dyslipidemia (43). 
 Dyslipidemia is the raised TG values (≥150 mg/dl, fasting), low high density 
lipoprotein (HDL) cholesterol values (<40 mg/dl in men, <50 mg/dl in women, fasting), 
increased small, dense low density lipoprotein (sd LDL) cholesterol values, and raised 
apolipoprotein (apo) B values, the structural protein of very low density lipoprotein 
(VLDL) and LDL (44).  Dyslipidemia is an independent risk factor for CVD (45). 
 
 
Table 1. Lipid and lipoprotein abnormalities in type 2 diabetes. 
Diabetes category Lipids and lipoproteins 
Usual levels of glycemia Increased triglycerides 
 Decreased HDL cholesterol 
 Small and dense LDL particles 
 Increased LDL susceptibility to oxidation 
Poor glycemic control Worsening of hyperglyceridemia 
Diabetic nephropathy Increased triglycerides 
 Decreased HDL cholesterol 
HDL, High Density Lipoprotein; LDL, Low Density Lipoprotein. 
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Hypertriglyceridemia (HTG) is characterized by the over secretion of TG-rich 
VLDL particles from the liver (46).  In abdominal obesity and insulin resistance, FFA 
release is increased (47).  Increased FFA uptake by the liver then stimulates the secretion 
of TG-rich VLDL in the blood stream.  In the peripheral circulation, TG in VLDL is 
hydrolyzed by LPL and the generated FFA is used by peripheral tissues (48). 
 
Lipoproteins and Apolipoproteins 
Lipoproteins are a molecular complex that carries various lipids and proteins in 
the circulation.  The cores of lipoproteins are filled with hydrophobic TG and cholesteryl 
ester molecules and these are covered with amphipathic (hydrophobic and hydrophilic) 
phospholipids and proteins (Table 2).   
Apolipoproteins are proteins that are located on the surface of the lipoproteins.  
They are involved in the regulation of plasma lipid and lipoprotein transport (Table 3).  
Apo A-I is the major structural protein of HDL and it activates lecithin cholesterol-acyl 
transferase (LCAT), playing a role in reverse cholesterol transport.  LCAT esterifies free 
cholesterol using a fatty acyl moiety derived primarily from phosphatidylcholine within  
 
Table 2. Characteristics of the lipoproteins. 
Lipid (%) Lipoprotein TG CHOL PL 
Chylomicrons 80-95 2-7 3-9 
VLDL 55-80 5-15 10-20 
IDL 20-50 20-40 15-25 
LDL 5-15 40-50 20-25 
HDL 5-10 15-25 20-30 
VLDL, Very Low Density Lipoprotein; IDL, Intermediate Density Lipoprotein; LDL, 
Low Density Lipoprotein; HDL, High Density Lipoprotein; TG, Triglyceride; CHOL, 
Cholesterol; PL, Phospholipid. 
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Table 3. Characteristics of the major apolipoproteins. 
Apolipoprotein Lipoproteins Metabolic functions 
A-I HDL, chylomicrons Structural component of HDL;LCAT activator 
A-II HDL, chylomicrons Unknown 
A-IV HDL, chylomicrons Unknown; possibly facilitates transfer of  
apolipoproteins between HDL and chylomicrons 
B-48 Chylomicrons Necessary for assembly and secretion of chylomicrons 
from the small intestine 
B-100 VLDL, IDL, LDL Necessary for the assembly and secretion of VLDL 
from the liver; structural protein of VLDL, IDL and 
LDL; ligand for the LDL receptor 
C-I VLDL, IDL, LDL, 
chylomicrons 
May inhibit hepatic uptake of chylomicrons; VLDL 
remnants 
C-II VLDL, IDL, LDL, 
chylomicrons 
Activator of lipoprotein lipase 
C-III VLDL, IDL, LDL, 
chylomicrons 
Inhibitor of lipoprotein lipase; inhibits hepatic uptake 
of chylomicron and VLDL remnants 
E VLDL, IDL, LDL, 
chylomicrons 
Ligand for binding of several lipoproteins to the LDL 
receptor, LRP, and proteoglycans 
HDL, High Density Lipoprotein; LCA,: Lecithin Cholesterol-Acyl Transferase; VLDL, Very Low 
Density Lipoprotein; IDL, Intermediate Density Lipoprotein; LDL, Low Density Lipoprotein; 
LRP, LDL-Receptor-related Protein. 
 
 
HDL particles (49).  Apo A-II is the second structural protein of HDL but its function is 
largely unknown (49).  The function of Apo-IV is also unknown and it may serve in 
apoproteins transfer between HDL and chylomicrons (50).  Apo B-48 helps to assemble 
TG, FFA, and PL with chylomicron in small intestine (51).  Apo B-100 is involved in 
secretion of VLDL, IDL, and LDL.  Apo C-II activates LPL (52). 
 
Free fatty acids 
Insulin resistance causes fat cells to break down more of their stored TG and 
release of more FFA into the circulation (53).  The primary defect is probably focused in 
the inability to incorporate the FFAs to TGs by the adipose tissue (44).  This results in 
reduced fatty acid trapping and retention by the adipose tissue.  The insulin resistance 
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also causes reduced retention of FFAs by adipocytes.  Both these abnormalities lead to 
increased flux of FFA to the liver (54) (Figure 2).   
 
Triglycerides 
Increased FFA from the periphery to the liver in the insulin resistant state 
stimulates hepatic TG synthesis by promoting assembly and secretion of TG containing 
VLDL (28), as well as the apo B production in the liver (55).  Also, when insulin 
resistance occurs, insulin becomes unable to suppress insulin on VLDL secretion (56) 
(Figure 2).  
 
Small dense LDL cholesterol 
In the insulin resistant state, the LDL levels are usually within normal limits or 
raised slightly.  However, the LDL particles have smaller and denser size (sdLDL).  It 
seems that the underlying abnormality causing sdLDL is hypertriglyceridemia, because it 
has been found that sdLDL is not seen until plasma TG levels exceed 150mg/dl (57).  
Under these conditions, large TG rich VLDL molecules accumulate, which results in 
increased TG rich LDL.  TG rich LDL is a good substrate for HL that finally generates 
sdLDL (58) (Figure 2). 
 
HDL cholesterol 
Under the increased plasma TG levels, the cholesteryl ester transfer protein 
mediates TG-cholesteryl ester exchange between LDL and VLDL.   Similar lipid TG rich  
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Figure 2. Schematic representation of dyslipidemia (58). 
FFA, Free Fatty Acid; TG, Triglyceride; HDL, High Density Lipoprotein; CETP, 
Cholesteryl Ester Transfer Protein; CE, Cholesterol Ester; VLDL, Very Low Density 
Lipoprotein; LDL, Low Density Lipoprotein; HL, Hepatic Lipase. 
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exchange is taking place between LDL and HDL particles, forming TG rich HDL.  These 
but cholesterol depleted HDLs undergo hydrolysis of their TG component and 
dissociation of their protein component, Apo A (the main protein of HDL) (59) (Fgure 2). 
 
4. Genetics in Type 2 Diabetes Mellitus and Dyslipidemia 
A. Humans 
Genetic factors account for about 50-70% of the causes of T2DM; other factors 
are environmental (such as high caloric diet and lack of activity) (60).  The prevalence of 
diabetes in offspring of patients with T2DM in both parents is about 60% by the age of 60 
years and in one parent is about 38% by the age of 80 years (61,62).  In addition, 15-24% 
of first-degree relatives of T2DM patients showed impaired glucose tolerance or diabetes 
(62). 
In a twin study, the prevalence rate of diabetes in individuals older than 60 years 
was 35-58% in monozygotic twins and 17-20% in dizygotic twins (63). The impaired 
glucose tolerance increased in monozygotic twins to 88% (64).  
Finding diabetic genes has been complicated because of the complexity and late 
onset of disease and limitation of family history of diabetes. Until now, it has been found 
that T2DM is polygenic and is caused by interaction of many genes (65).  To identify 
these genes and their interactions it is necessary to study a very large population (66).  
Thus far, two loci for obesity associated non-insulin dependent diabetes mellitus 
(NIDDM), NIDDM1 and NIDDM2, have been found on chromosome 2q in Mexican –
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American populations (67) and on chromosome 12q in western Finland population (68), 
respectively. 
 
B. Animals 
Animal models of T2DM are likely to be as complex and heterogeneous as the 
human condition. (69),  However, finding diabetes genes in rodents offer advantages over 
humans because a large number of animals can be bred for study, and the environmental 
influence and genetic heterogeneity can be controlled (66).   
Quantitative trait loci (QTLs) mapping is a genome-wide inference of the 
relation between genotype and phenotype.  Detecting and mapping QTL method has been 
used since Thoday’s study (70).  The purpose of QTL mapping is to localize 
chromosomal regions that significantly affect the variation of quantitative traits in a 
population.  From this location in the chromosome, scientists attempt to find candidate 
genes (71).  For QTL mapping, it is necessary to cross two differentiated populations and 
then either backcross to the parents to create backcross population or intercross between 
brother and sister to create F2 progeny.  The backcross or F2 populations are then 
phenotyped and genotyped using genetic markers (72) (Figure 3).  Most frequently used 
genetic markers include simple sequence length polymorphic (SSLP) markers that consist 
of a variable number of cytosine-adenine repeats (CA)n.  These repeats are present at 
~1,000,000 copies per genome (73).  
 Using QTL mapping analysis, several loci linked to dyslipidemia have been 
identified in numerous genetic crosses of rodents. 
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Figure 3. Steps in quantitative trait locus mapping (72). 
 
 
1) QTLs for  plasma triglyceride levels in mice. 
In KK/Ta x (BALB/c x KK/Ta)F1 mice, QTLs for serum TG levels were found on 
chromosomes 8 (51.5 cM)) and 4 (59 cM) (74).  In the C57BL/6J x 129S1/SvImJ mice, 
QTLs linked to plasma TG levels were also found on chromosome 18 (42 cM), 9 (66cM) 
and 4 (58cM) (75).  In the LG/J x SM/J mice, QTLs for plasma TG levels were detected 
on chromosomes 11 (9 cM), 1 (95.8 cM), and 4 (58 cM) (76).   Additionally, in the SM/J 
x A/J recombinant inbred mice, QTLs for plasma TG levels were detected on 
chromosomes 11 (70 cM), 9 (33 cM), and 8 (30 cM) (77) (Table 4). 
Strain 1 
(BB) 
Strain 2 
(TT) 
F2 Progeny 
(BB, BT, TT) 
Backcross Progeny 
(BB, BT or BT, TT) 
Measure Phenotype of Each progeny 
(e.g. body fat, rate of growth) 
and 
Determine Genotype of Each progeny at Each Marker
(i.e. assay for B and T alleles) 
↓ 
Statistically Associate Genotype with Phenotype 
Cross phenotypically 
divergent inbred strains
F1 
(BT) 
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Table 4. QTLs for plasma triglyceride levels in mice. 
Strains Chr cM Symbol, name Ref.
KK/Ta x  
(BALB/c x KK/Ta)F1 8 51.5 Tgl1, triglyceride level 1 (74)
 4 59 Tgls1, triglyceride level suppressor 1  
C57BL/6J x  
129S1/SvImJ 18 42 Tgq1, triglyceride QTL 1 (75)
 9 66 Tgq2, triglyceride QTL 2  
 4 58 Tgq3, triglyceride QTL 3  
LG/J x SM/J 11 9 Tgyl1, triglyceride level 1 (76)
 1 95.8 Trglyd, triglycerides  
 4 58 Triglq1, triglyceride QTL 1  
SM/J x A/J 11 70 Triglq2, triglyceride QTL 2 (77)
 9 33 Trigq1, triglyceride QTL 1  
 8 30 Trigq2, triglyceride QTL 2  
Chr, Chromosome; cM, Centimorgan; Ref, Reference. 
 
 
2) QTLs for plasma cholesterol levels in mice 
In KK/Ta x (BALB/c x KK/Ta)F1 mice, a QTL for serum total cholesterol levels 
was found on chromosome 3 (49.2 cM)) (74).  In the C57BL/6J x C3H/He mice, QTLs 
linked to plasma total cholesterol were also found on chromosomes 7 (65 cM) and 6 (2.9 
cM) (78).  In the 129S1/SvImJ x RIIIS/J mice, significant QTLs associated with serum 
cholesterol levels were detected on chromosome 9 (9 and 28 cM) (79).  In the DBA/2J x 
CAST/Ei mice, a QTL on chromosome 9 (5 cM) was linked to plasma total cholesterol 
levels (80).  In the 129S1/SvImJ x  CAST/Ei mice, QTLs for plasma cholesterol levels 
were also found on chromosomes 1 (74 cM), 4 (12 cM) and 17 (54 cM) (81).  In the KK 
x KK-Ay mice, QTLs for plasma cholesterol levels were also found on chromosomes 1 
(74 and 100 cM) and 3 (49.7 cM) (82).  In the C57BL/6J x RR mice, a QTL for plasma 
cholesterol levels was also found on chromosome 1 (100 cM) (81) (Table 5). 
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Table 5. QTLs for plasma cholesterol levels in mice. 
Strains Chr cM Symbol, name Ref. 
KK/Ta x  
(BALB/c x KK/Ta)F1 3 49.2 Tchol1, total cholesterol level 1 (74) 
C57BL/6J x C3H/He 7 65 Chol1, cholesterol 1 (78) 
 6 2.9 Chol2, cholesterol 2  
129S1/SvImJ x RIIIS/J 9 9 Chol10, cholesterol 10 (79) 
 9 28 Chol11, cholesterol 11  
DBA/2J x CAST/Ei 9 5 Chol6, cholesterol 6 (80) 
129S1/SvImJ x 
 CAST/Ei 1 74 Chol7, cholesterol 7 (83) 
 4 12 Chol8, cholesterol 8  
 17 54 Chol9, cholesterol 9  
KK x KK-Ay 1 81.6 Cq1, cholesterol QTL 1 (82) 
 1 100 Cq2, cholesterol QTL 2  
 3 49.7 Cq3, cholesterol QTL 3  
C57BL/6J x RR 1 100 Cq6, cholesterol QTL 6 (81) 
Chr, Chromosome; cM, Centimorgan; Ref, Reference. 
 
 
3) QTLs for plasma insulin levels in mice. 
In the DU6i x DBA/2 mice, QTLs associated with plasma insulin were detected on 
chromosome 10 (38 cM) and 18 (39 cM) (84).  In the NOR/Lt x NOD/Jsd mice, QTLs 
for plasma insulin levels were found on chromosomes 17 (19.5 cM), 9 (55 cM), 3 (19.2 
cM), 11 (46 cM), 1 (40 cM) and 6 (73 cM) (85-88) (Table 6). 
 
4) QTLs for plasma glucose levels in mice. 
In the C57BL/6 x C3H/He mice, QTLs associated with plasma glucose were detected 
on chromosomes 2 (87 cM) and 13 (59 cM) (89).  In the KK/Ta x (BALB/c x KK/Ta)F1  
mice, QTLs for plasma glucose were found on chromosomes 12 (36 cM) and 15 (10.1 
cM) (74).  In the KK x KK-Ay  mice, QTLs for plasma glucose were found on 
chromosomes 6 (16 cM), 1 (100 cM) and 15 (10.1 cM) (74,90) (Table 7). 
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Table 6. QTLs for plasma insulin levels in mice. 
Strains Chr cM Symbol, name Ref.
DU6i x DBA/2 10 38 Igf1q1, insulin-like growth factor 1 QTL 1 (84)
 18 39 Igf1q2, insulin-like growth factor 1 QTL 2  
17 19.5 Idd1, insulin dependent diabetes susceptibility 1 (85)NOR/Lt x 
NOD/Jsd 9 55 Idd2, insulin dependent diabetes susceptibility 2  
 3 19.2 Idd3, insulin dependent diabetes susceptibility 3 (86)
 11 46 Idd4, insulin dependent diabetes susceptibility 4  
 1 40 Idd5, insulin dependent diabetes susceptibility 5 (87)
 6 73 Idd6, insulin dependent diabetes susceptibility 6 (88)
Chr, Chromosome; cM, Centimorgan; Ref, Reference; NOD, Nonobese Diabetic mice; 
NOR, Nonobese Diabetes Resistance mice. 
 
 
 
 
Table 7. QTLs for plasma glucose levels in mice. 
Strains Chr cM Symbol, name Ref. 
C57BL/6 x C3H/He 2 87 Bglu1, blood glucose level 1 (89) 
 13 59 Bglu2, blood glucose level 2  
KK/Ta x (BALB/c 
x KK/Ta)F1 12 36 Fbgl1, fasting blood glucose 1 (74) 
 15 10.1 Fbgl2, fasting blood glucose 2  
KK x KK-Ay 6 16 Fglu, fasting glucose (90) 
 1 100 Fglu2, fasting glucose 2  
 6 2.8 Imgt1, impaired glucose tolerance 1 (74) 
Chr, Chromosome; cM, Centimorgan; Ref, Reference. 
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5) QTLs for body weight in mice. 
In the C57BL/6J x PERA/Ei mice, a QTL associated with body weight was 
detected on chromosome 8 (16 cM) (91).  In the C57BL/6J x FGS/Kist  mice, a QTL for 
body weight was found on chromosome 13 (9 cM) (92).  In the DU6i x DBA/2  mice, 
QTLs for body weight were found on chromosomes 2 (18 cM), 11 (55 cM), 1 (5 cM), and 
9 (34 cM) (90), (93).  In the C57BL/6J x TallyHo, QTLs for body weight were found on 
chromosomes 7 (30 cM) and X (16 and 32 cM) (94).  In the DU6 x DUKs mice, QTLs 
for body weight were found on chromosomes 1 (36 and 69 cM), 2 (56 cM), 4 (59 cM),  5 
(81 and 82 cM), 6 (35 cM), 7 (28 cM), 11 (14 and 55 cM), 12 (17 cM), 13 (10 and 34 
cM),  15 (6 cM), and X (42 cM) (95) (Table 8). 
 
6) QTLs for fat weight in mice 
In the NSY x C3H/He mice, a QTL associated with epididymal fat pad weight 
was detected on chromosome 6 (35 cM) (96).  In the C57BL/6J x TallyHo mice, a QTL 
for mesenteric fat pad weight was found on chromosome 4 (69.8 cM) (97).  In the MH x  
ML mice, QTLs for brown fat pad weight were found on chromosomes 1 (102 cM) and 3 
(55 cM) (98) (Table 9). 
 
5. Polygenic Rodent Models of Type 2 Diabetes Mellitus  
The Goto Kakizaki (GK) rat 
 The GK rat is used to understand pathogenesis of nonobese T2DM (99).  The GK  
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Table 8. QTLs for body weight in mice. 
Strains Chr cM Symbol, name Ref. 
C57BL/6J x PERA/Ei 8 16 Bdwt, body weight (91) 
C57BL/6J x FGS/Kist 13 9 Bdw1, body weight 1 (92) 
DU6i x DBA/2 2 18 Bodw1, body weight 1 (93) 
 11 55 Bodw2, body weight 2  
 1 5 Bodw3, body weight 3  
 9 34 Bodw4, body weight 4  
C57BL/6J x TallyHo 7 30 Tabw, TallyHo associated body weight (97) 
 X 18 BW1, body weight QTL 1 (94) 
 X 32 BW3, body weight QTL 3  
DU6 x DUKs 11 55 BW4, body weight QTL 4 (95) 
 1 36 BW5, body weight QTL 5  
 2 56 BW6, body weight QTL 6  
 4 59 BW7, body weight QTL 7  
 5 82 BW8, body weight QTL 8  
 12 17 BW9, body weight QTL 9  
 13 34 BW10, body weight QTL 10  
 15 6 BW11, body weight QTL 11  
 X 42 BW12, body weight QTL 12  
 5 81 BW13, body weight QTL 13  
 7 28 BW14, body weight QTL 14  
 13 10 BW15, body weight QTL 15  
 11 14 BW16, body weight QTL 16  
 1 69 BW17, body weight QTL 17  
 6 35 BW18, body weight QTL 18  
Chr, Chromosome; cM, Centimorgan; Ref, Reference. 
 
 
 
Table 9. QTLs for fat weight in mice. 
Strains Chr cM Symbol, name Ref. 
NSY x C3H/He 6 35 Efw, epididymal fat weight (96) 
C57BL/6J x  
TallyHo 4 69.8 Tafat, TallyHo associated fat (97) 
MH x ML  1 102 Batq1, brown fat QTL 1 (98) 
 3 55 Batq2, brown fat QTL 2  
Chr, Chromosome; cM, Centimorgan; Ref, Reference. 
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rats develop relatively stable hyperglycaemia in adult life. Typically, the fasting blood 
glucose is only mildly elevated but rises further on challenge with glucose. Both insulin  
resistance and impaired insulin secretion are present. This rat is usually born with a 
reduced number of islets (100). 
 
Spontaneously Diabetic Torii (SDT) rat 
 SDT rats are an inbred strain with spontaneous diabetes without obesity 
originated from an outbred colony of Sprague-Dawley rats (101).  This rat spontaneously 
develops hyperglycemia and glucosuria after 20 weeks of age with an incidence of 100% 
at 40 weeks of age in males.  Moreover, SDT rats exhibit severe ocular complications 
such as proliferative retinal degeneration and detachment of retina resembling human 
diabetic retinopathy (101).  
 
The Otkuka Long-Evans Tokushima fatty (OLETF) rat 
 The OLETF rats are generated from an outbred colony of Long-Evans rats by  
selective breeding for glucose intolerance (102).  The rats are mildly obese and males are 
more likely to develop diabetes in adult life than females. Genome wide scans have 
revealed susceptibility loci for T2DM-related traits on chromosomes 1, 7, 14, and X 
(103,104).  It has also been known that OLETF rats carry a null allele for the 
cholecystokinin A receptor which may be involved in the regulation of food intake in 
these rats (105).  However, whether this is casually related to the phenotype is still 
unclear (69). 
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 The KK mouse 
The original strain of KK mouse was bred for large body size (106).  KK mice 
exhibit a multigenic syndrome of hyperphagia, moderate obesity, hyperinsulinemia, and 
hyperglycemia (106,107).  Male mice but females develop T2DM after 4 months of age 
(108).  KK/Ay mouse, a congenic strain of the Ay allele at the agouti locus in the KK 
background, also develops T2DM that is more severely expressed than that in KK.  These 
mice are a suitable model for the study of maturity onset obesity and diabetes in humans 
(90). 
 
The Nagoya-Shibata-Yasuda (NSY) mouse 
 NSY mice spontaneously develop diabetes in an age-dependent manner (96). 
These mice develop diabetes at a very late age with mild obesity and mild insulin 
resistance. Almost all males develop hyperglycemia, but less than a third of females do 
(96). This gender difference is a general characteristic of most rodent models of T2DM. 
 
The New Zealand Obese (NZO) mouse 
  The NZO mice are an inbred strain initially selected for polygenic obesity, 
characterized by hyperphagia, obesity and insulin resistance (109).  These mice have 
been used to characterize the interactions of obesity and diabetes genes (110). 
 
TALLYHO (TH) mouse 
 The TH mouse strain was originally derived from a colony of outbred Theiler 
Original mice which show polyuria and glucosuria  (97).  The TH mice have been 
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established by selective breeding based on the hyperglycemia phenotype of the original 
deviant stock. TH mice exhibit obesity, hyerinsulinemia, hyperlipidemia, and 
hyperglycemia (male).  A genome-wide linkage analysis using backcross progeny from a 
cross of F1(B6 x TH) and TH mice revealed QTLs linked to body weight on 
chromosomes 6 and 7 and a QTL affecting hyperglycemia on chromosome 19 (97).    
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Chapter III: Experimental section 
 
Abstract 
Type 2 diabetes mellitus (T2DM) is a chronic disease and closely associated with 
altered lipid metabolism in humans that often predates the onset of full-blown diabetes.  
It is well-established that genetic factors significantly influence the development of 
dyslipidemia, yet no susceptibility genes for the dyslipidemia have been identified in 
humans.  TALLYHO/JngJ (TH) strain of mice is a polygenic model of T2DM with 
obesity and characterized by insulin resistance, hyperinsulinemia, hyperglycemia, and 
hyperlipidemia.  In a previous study, we have identified that plasma triglyceride (TG) 
levels are dramatically increased in TH male mouse at 10 wks while plasma insulin levels 
steadily increased before the onset of diabetes at 30 wks.  In order to identify the 
underlying genetic factors responsible for the hypertriglyceridemia (HTG) in the TH 
mouse, we intercrossed F1 (C57BL/6J x TH) mice to produce F2 mice and all F2 mice 
were genotyped using 67 simple sequence length polymorphic markers covering the 
whole genome.  Mice were fasted 4 hours from 7:00 to 11:00 AM, blood was collected at 
8, 12, 16, 20, and 24 weeks (wk) of age, and plasma glucose, insulin, free fatty acids, TG 
and total cholesterol levels were measured.  Body weights were also measured at the 
same time.  At the age of 24 wk, mice were killed and five white fat pads (inguinal, 
epididymal, mesenteric, retroperitoneal, and subscapular) and brown fat pad were 
dissected and weighed.  With the genotype and phenotype data of F2 mice, we conducted 
QTL analysis using the computer program, Map Manager.  In 182 male F2 mice, 
significant evidence for linkage with plasma TG levels was detected on chromosome 1 at 
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marker D1Mit113 (93 cM).  This QTL was also significantly linked to plasma total 
cholesterol levels.  In addition, a highly significant linkage for the plasma glucose levels 
was detected at marker D4Mit178 located at chromosome 4 (36 cM).  For all these traits, 
mice homozygous for TH alleles exhibited higher values than mice heterozygous or mice 
homozygous for B6 alleles.  In summary, our genetic study revealed a complex pattern of 
inheritance for HTG and diabetes and mapped significant QTLs on chromosome 1 for 
HTG and on chromosome 4 for hyperglycemia in TH mice.  
 
1. Introduction 
Type 2 diabetes mellitus (T2DM) is characterized by decreased insulin action 
and secretion and increased hepatic glucose production (111).  T2DM is associated with a 
variety of risk factors for cardiovascular disease, including elevated triglycerides and 
small, dense low-density lipoprotein cholesterol levels, and decreased high-density 
lipoprotein cholesterol levels and obesity.  This dyslipidemia is often found before the 
onset of diabetes in patients (112).  Hypertriglyceridemia (HTG) is recognized as a major 
dyslipidemic feature present in type 2 diabetic patients and as an independent risk factor 
for coronary artery disease (111).   
The importance of the genetic control of lipid metabolism has been demonstrated 
through epidemiological studies illustrating that 30 to 45% of the phenotypic variance for 
lipid and lipoprotein phenotypes is accounted by genes whereas environmental factors 
account for less than 15% of the variance (113).  Indeed, many studies have identified the 
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genomic regions or the candidate genes that affect HTG traits in humans on 
chromosomes 2, 6, 7, 11, and 15 (114-116), in rat on chromosomes 2, 4, 6, 8, and 17 
(117-121), and in mouse on chromosomes 4, 8, 9, 11, 12, and 19 (74,77,122-124) using 
quantitative trait locus (QTL) mapping. 
TALLYHO/JngJ (TH) mice are a newly established inbred polygenic model for 
T2DM.  TH mice are characterized by insulin resistance, hyperinsulinemia, diabetes, 
obesity and dyslipidemia (increased TG, free fatty acids (FFA) and cholesterol levels) 
(97). Our longitudinal metabolic study revealed that TH male mice, but not females, 
rapidly developed HTG at a very young age before the onset of overt diabetes. The HTG 
was accompanied by hyperinsulinemia, but preceded glucose intolerance (97).   
The objective of this study was to identify the underlying genetic susceptibility 
loci responsible for the HTG in the TH mice.  Dissecting the existing genetic variation 
into loci and mapping them to chromosomal regions are the initial steps for the ultimate 
identification of genetic factors and their molecular bases.  Therefore, the present study 
will provide valuable information for understanding the pathogenic mechanism of 
diabetic dyslipidemia and for finding the therapeutic targets. 
 
2. Materials and Methods 
Animals: All mice were allowed free access to food and water in a temperature- and 
humidity-controlled room with a 12:12-h light-dark cycle.  Mice were fed a standard 
rodent chow [4% fat, Harlan Teklad Rodent Diet (W) 8604, Harlan Teklad; Madison, WI].  
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All animal studies were carried out with the approval of The University of Tennessee 
Animal Care and Use Committee. 
Genetic Crosses:  Hypertriglyceridemic male TH mice were mated to normal female 
C57BL/6J (B6) mice.  The resulting F1 hybrid mice were interbred to produce an F2 
population in which the genomes of the parental strains are reshuffled by recombination 
resulting in segregation of HTG and related traits.  Since female TH mice do not develop 
severe HTG only male F2 mice were used for mapping the genetic susceptibility loci for 
HTG (97). 
Phenotype analysis: Blood was collected from the retro-orbital plexus using 
heparinized microcapillary tubes (no.22-362-566, Fisher Scientific; Pittsburgh, PA) after 
4 hour (7:00 - 11:00 A.M.) fasting at 8, 12, 16, 20, and 24 weeks (wk) of age, and plasma 
was obtained by centrifugation (1,200 g) at 4 °C.  The plasma TG, glucose, total 
cholesterol and FFA levels were analyzed colorimetrically using commercial assay kits 
(Sigma no. TR0100, Sigma no. 510, Sigma no. 401, Roche no. 1-383-175, respectively) 
as per manufacturer’s specifications and insulin using RIA kits (no. RI-13K, Linco 
Research; St. Charles, MO).  At the age of 24 wk, mice were euthanized by CO2 
asphyxiation and five white fat pads [inguinal, epididymal, mesenteric, retroperitoneal 
(including perirenal), and subscapular] and brown fat pad were dissected and weighed. 
Genotyping: Genomic DNA was prepared from tail tips using proteinase K and two 
series of salt precipitation steps (125).  The DNA was amplified by PCR using 67 simple 
sequence length polymorphic (SSLP) markers (MapPairs, Invitrogen; Carlsbad, CA) 
(Table 10), covering the 19 autosomal chromosomes.  The thermal cycle consisted of 
94°C for 2 min followed by 49 cycles of 94°C (20 s), 50°C (30 s), and 72°C (40 s) and  
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Table 10. Simple sequence length polymorphic markers used for genome scan of F2 mice 
from an intercross of F1(C57BL/6J x TALLYHO/JngJ) mice. 
Marker cM Marker cM 
Chromosome 1 D9MIt212 61.0 
D1Mit213  25.7 Chromosome 10 
D1Mit215  47.0 D10Mit80 4.0 
D1Mit26   62.1 D10Mit130 31.5 
D1Mit113  93.9 D10Mit11 50.0 
D1Mit206  95.8 Chromosome 11 
Chromosome 2 D11Mit20 20.0 
D2Mit1   1.0 D11Mit86 28.0 
D2Mit296  18.0 D11Mit41 49.0 
D2Mit56  41.0 D11Mit132 58.0 
D2Mit17  69.0 Chromosome 12 
D2Mit22  84.0 D12Mit83 6.0 
D2Mit200 107.0 D12Mit34 29.0 
Chromosome 3 D12Mit233 52.0 
D3Mit304    5.6 Chromosome 13 
D3Mit40  39.7 D13Mit205 5.0 
D3Mit106 55.0 D13Mit35 75.0 
Chromosome 4 D13Mit26 38.0 
D4Mit97   6.3 D13Mit148 59.0 
D4Mit178  35.5 Chromosome 14 
D4Mit37  56.5 D14Mit53 12.5 
D4Mit312  69.8 D14Mit102 28.3 
D4Mit42  81.0 D14Mit107 63.0 
D4Mit208 81.5 Chromosome 15 
Chromosome 5 D15Mit174 6.7 
D5Mit193   1.0 D15MitNDS2  
D5Mit20  52.0 D15Mit2 46.9 
D5Mit101 81.0 Chromosome 16 
Chromosome 6 D16Mit181 4.3 
D6Mit93 26.29 D16Mit152 57.0 
D6Mit29 36.5 D16Mit4 27.3 
D6Mit339 65.5 Chromosome 17 
Chromosome 7 D17Mit133 10.4 
D7Mit306 1.7 D17Mit123 56.7 
D7Mit231 27.8 D17Mit54 38.5 
D7Mit109 66.0 Chromosome 18 
Chromosome 8 D18Mit68 11.0 
D8Mit95 8.0 D18Mit47 50.0 
D8Mit339 23.0 D18Mit53 27.0 
D8Mit242 47.0 Chromosome 19 
Chromosome 9 D19Mit71 54.0 
D9Mit323 6.0 D19Mit66 41.0 
D9Mit142 31.0 D19Mit30 20.0 
cM, centimorgan; The genetic positions of marker loci were based on Mouse Genome Database 
map locations. 
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final extension at 72°C (7 min).  Amplified products were electrophoretically separated 
on 3% metaphor (no. 50184, FMC; Rockland ME)/1% agarose (no. 0710-500G, 
Amresco; Solon, OH) gels in 0.5 x Tris-borate-EDTA buffer, pH 7.4.  The DNA was 
visualized by ethidium bromide (no. E-1510, Sigma, St, Louis, MO) staining (126).  
QTL analysis: QTL analysis was performed using the computer program, Map 
Manager QT (www.mapmanager.org/mmQTX.html).  We used two main functions of 
Map Manager QT for identifying and locating possible quantitative trait loci 
(http://www.mapmanager.org/mmQT.html#anchor1452245). We analyzed genetic 
markers to identify those which are significantly associated with the trait of interest 
according to simple regression analysis.  We also searched analyzed markers with an 
interval regression method to map quantitative traits within the intervals defined by the 
markers (127).  In addition, we conducted permutation test to assess the statistical 
significance of any putative QTL (128).  The permutation test estimates an empirical 
genome-wide probability for given likelihood ratio statistics (LRS) generated by interval 
mapping (129). Significance was determined by 1,000 permutations to provide LRS that 
were suggestive, significant or highly significant.  The suggestive, significant, and highly 
significant correspond to the 90th, 95th and 99.9th percentiles (128).  
For each QTL, we determined the allelic effect by calculating the phenotype mean 
for each of the three possible genotypes (homozygous for TH allele, homozygous for B6 
allele and heterozygous).  We then determined qualitatively which strain contributed the 
allele that increased phenotypic values and inferred whether that allele caused dominant, 
additive, or recessive inheritance of the phenotype of interest.  A dominant allele was 
defined as exhibition of a high level by the heterozygous genotype indistinguishable from 
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the high-phenotype homozygous genotype, whereas a recessive allele was defined as the 
heterozygous genotype being indistinguishable from the low-phenotype homozygous 
genotype.  An additive allele was defined as an allele that produced a intermediate 
phenotype between each of the homozygous-low and homozygous-high genotypes (79).  
Statistical differences in trait values among parental strains and among genotypes in F2 
were analyzed by ANOVA with StatView 5.0 (Abacus Concepts, Berkely, CA).  All data 
are presented as mean ± SEM. 
 
3. Results 
Phenotypic characteristics of parental strains and F1(B6 x TH) mice. 
TH mice had heavier body weights and fat pad weights than B6 mice (Table 11).  
The body weights of F1(B6 x TH) mice were similar to the TH mice, but significantly 
higher than B6 mice (Table 11).  On the other hand, fat pad weights of F1 mice were 
significantly higher than TH mice (except mesenteric) as well as B6 mice (Table 11). 
The mean plasma glucose, TG, total cholesterol, and insulin levels in the TH mice 
were all significantly higher than B6 or F1 mice (except for plasma insulin levels) (Table 
11).  The plasma glucose levels of F1 mice were similar to those of B6 mice, suggesting 
recessive inheritance of this trait.  On the other hand, the plasma TG levels of F1 mice 
were intermediate between the means of the two parental strains (Table 11) 
semidominance, suggesting that the trait was controlled by both B6 and TH alleles (131).  
Total plasma cholesterol levels of F1 mice were not significantly different from B6 at 8 
wk - 16 wk, but became significantly higher at 20 wk and 24 wk.  The plasma insulin  
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Table 11. Phenotypic characteristics of parental strains and F1 progeny (males). 
Phenotype B6 TH F1 P-value 
    B6 vs TH B6 vs F1 TH vs F1 
Body weight (g)      
8 week 22.1 ±0.4 (14) 30.8±0.5(7) 30.0±0.5(15) <0.0001 <0.0001 NS 
12 week 23.9±0.5(18) 31.8±0.6(16) 33.4±0.6(19) <0.0001 <0.0001 Ns 
16 week 25.4±0.5(18) 34.4±0.8(16) 36.2±0.7(19) <0.0001 <0.0001 NS 
20 week 26.8±0.5(18) 35.9±1.0(16) 38.3±0.7(19) <0.0001 <0.0001 NS 
24 week 27.5±0.4(18) 35.0±1.5(16) 40.0±0.7(19) <0.0001 <0.0001 0.0029 
Plasma glucose (mg/dl)      
8 week 174.6±9.9(9) 292.1±47.6(7) 174.6±11.3(15) 0.0019 NS <0.0001 
12 week 132.1±6.4(14) 252.1±39.6(9) 146.7±8.6(19) <0.0001 NS <0.0001 
16 week 181.3±13.7(19) 460.5±37.9(16) 166.4±4.2(19) <0.0001 NS <0.0001 
20 week 177.3±10.4(18) 363.8±35.8(16) 156.1±5.0(19) <0.0001 NS <0.0001 
24 week 174.6±9.7(18) 387.5±32.6(16) 162.3±8.3(19) <0.0001 NS <0.0001 
Plasma triglyceride (mg/dl)      
8 week 62.7±12.2(9) 437.6±41.0(7) 153.0±11.8(15) <0.0001 0.0005 <0.0001 
12 week 68.2±7.7(14) 236.6±53.5(9) 186.1±10.7(19) <0.0001 <0.0001 0.0484 
16 week 63.0±2.6(18) 437.9±38.7(16) 168.3±8.2(19) <0.0001 <0.0001 <0.0001 
20 week 70.6±7.4(18) 367.2±31.7(16) 179.8±21.0(19) <0.0001 <0.0001 <0.0001 
24 week 59.7±5.7(18) 367.8±32.8(16) 221.2±18.6(19) <0.0001 <0.0001 <0.0001 
Plasma total cholesterol (mmol/l)     
8 week 2.9±0.2(9) 4.0±0.1(7) 2.3±0.1(15) <0.0001 NS <0.0001 
12 week 2.6±0.2(14) 2.9±0.1(9) 3.1±0.2(19) NS NS NS 
16 week 3.0±0.3(19) 3.6±0.3(16) 2.6±0.1(19) 0.0478 NS 0.0002 
20 week 2.1±0.1(18) 4.8±0.3(16) 3.5±0.3(19) <0.0001 0.0001 <0.0001 
24 week 1.9±0.1(18) 4.0±0.4(16) 3.6±0.1(19) <0.0001 0.0002 NS 
Plasma free fatty acid (mmol/l)     
8 week 0.8±0.07(9) 0.8±0.07(7) 0.6±0.03(15) NS NS NS 
12 week 0.9±0.09(14) 0.5±0.04(9) 0.7±0.08(19) 0.0014 NS NS 
16 week 0.6±0.07(18) 0.8±0.09(16) 0.5±0.03(19) NS NS NS 
20 week 0.6±0.09(18) 0.4±0.06(16) 0.5±0.09(19) NS NS NS 
24 week 0.7±0.08(18) 0.8±0.10(16) 0.6±0.06(19) NS NS NS 
Plasma insulin (ng/ml)      
8 week 0.07±0.02(9) 1.8±0.41(7) 1.0±0.17(15) <0.0001 0.0209 0.0446 
12 week 0.2±0.07(13) 1.0±0.33(9) 1.1±0.15(19) 0.0112 0.0298 NS 
16 week 0.4±0.09(18) 1.0±0.26(15) 1.2±0.13(19) 0.0112 NS NS 
20 week 0.4±0.11(18) 1.6±0.41(16) 2.1±0.26(19) 0.0058 0.0201 NS 
24 week 0.4±0.10(10) 2.3±0.56(13) 2.8±0.55(16) 0.0186 0.0390 NS 
Fat pad and carcass weights (g, 24wk)     
Ing 0.34±0.02 0.69±0.15 1.40±0.07 0.0190 <0.0001 <0.0001 
Epi 0.43±0.03 0.98±0.23 1.86±0.07 0.0048 <0.0001 <0.0001 
Mes 0.11±0.01 0.24±0.06 0.11±0.03 0.0399 <0.0001 <0.0001 
Retro 0.12±0.06 0.26±0.06 0.64±0.02 0.0294 <0.0001 <0.0001 
Subsc 0.14±0.01 0.32±0.09 0.72±0.04 NS <0.0001 0.0002 
TF 1.14±0.06 2.34±0.55 5.17±0.20 0.0217 <0.0001 <0.0001 
BF 0.07±0.003 0.22±0.02 0.23±0.01 <0.0001 <0.0001 NS 
Carcass 25.52±0.37 30.84±1.05 33.63±0.48 <0.0001 <0.0001 0.0223 
Values represent mean ±SEM; NS, not significant. The number of mice used for the tests is provided in the 
parentheses. The P-values were generated by the Student’s t-test. Ing, inginal fat pad; Retro, retroperitoneal (including 
perirenal) fat pad; Epi, epididymal fat pad; Mes, mesenteric fat pad; Subsc, subscapular fat pad; TF, total fat pad [the 
sum of inguinal, epididymal, mesenteric, retroperitoneal (including perirenal), and subscapular fat pad weights]; 
Carcass, body weight without the total fat pad. 
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levels of F1 mice were significantly higher than those of the B6 mice (except at 16 wk) 
(Table 11). 
No significant differences in plasma free fatty acid levels were found among the 
parentals and F1 mice (Table 11). 
 
Phenotypic characteristics of F2 intercross mice. 
  The F2 mice showed a wide distribution pattern of the plasma glucose, TG, 
and cholesterol levels at all ages determined, indicating polygenic characteristics of the 
traits (Figures 4-10).   
 
QTLs controlling plasma TG levels.  
We found significant linkages for HTG at D1Mit113 on chromosome 1 and at 
D8Mit242 on chromosome 8, explaining 16.3% and 18.8% phenotypic variance of the 
trait, respectively (Table13).   Homozygous mice for TH alleles exhibited significantly 
higher plasma TG levels than mice homozygous for B6 and heterozygous at these loci.  
Also, the marker D10Mit11 exhibited a highly significant linkage with plasma TG levels 
at 16 wk and explained 30.6% phenotypic variance of the trait (Table 12).  Even though 
TH is the HTG-susceptible strain, the heterozygotes showed significantly higher plasma 
TG levels than mice homozygous for the TH allele at this locus (Table 12).  
 
QTLs controlling for plasma glucose levels. 
 A highly significant linkage for plasma glucose levels (at 20 wk) was found at 
marker D4Mit178 on chromosome 4, accounting for 23% of the phenotypic variance of 
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Figure 4. Histogram for plasma glucose levels in F2 male mice (n=182) from an 
intercross of F1(B6 x TH) mice.  Mice were fasted for 4 hours (7:00 – 11:00 A.M.), blood 
was collected and plasma glucose levels were then measured. 
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Figure 5. Histogram for plasma triglyceride levels in F2 male mice (n=182) from an 
intercross of F1(B6 x TH) mice.  Mice were fasted for 4 hours (7:00 – 11:00 A.M.), blood 
was collected and plasma triglyceride levels were then measured. 
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Figure 6. Histogram for plasma total cholesterol levels in F2 male mice (n=182) from an 
intercross of F1(B6 x TH) mice.  Mice were fasted for 4 hours (7:00 – 11:00 A.M.), blood 
was collected and plasma total cholesterol levels were then measured. 
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Figure 7. Histogram for plasma free fatty acid level in F2 male mice (n=182) from an 
intercross of F1(B6 x TH) mice.  Mice were fasted for 4 hours (7:00 – 11:00 A.M.), blood 
was collected and plasma free fatty acid levels were then measured. 
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Figure 8. Histogram for plasma insulin levels in F2 male mice (n=182) from an intercross 
of F1(B6 x TH) mice.  Mice were fasted for 4 hours (7:00 – 11:00 A.M.), blood was 
collected and plasma insulin levels were then measured. 
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Figure 9. Histogram for body weight in F2 male mice (n=182) from an intercross of 
F1(B6 x TH) mice. 
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Figure 10. Histogram for fat pad and carcass weights in F2 male mice (n=182) at 24 wks 
from an intercross of F1(B6 x TH) mice. 
Ing, inginal fat pad; Retro, retroperitoneal (including perirenal) fat pad; Epi, epididymal 
fat pad; Mes, mesenteric fat pad; Subsc, subscapular fat pad; Total fat pad, the sum of 
inguinal, epididymal, mesenteric, retroperitoneal (including perirenal), and subscapular 
fat pad weights; Carcass, body weight without the total fat pad. 
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Table 12. Highly significant QTLs in F2 mice from an intercross of F1(B6 x TH) mice 
(males). 
Phenotype values p value Marker (cM) Trait Wk % B/B H (B/T) T/T B vs H B vs T T vs H
Chr 4          
D4Mit178(35.5) Glu 20 23 145.0±3.3(36) 157.3±2.7(99) 177.8±7.6(36) 0.0377 <.0001 0.0007
Chr 10          
D10Mit11 (50) TG 16 30 143.3±6.5(73) 209.6±12.0(43) 141.3±10.3(40) <.0001 NS <.0001
Data are presented as mean ± SE; Chr, chromosome; Glu, plasma glucose levels (mg/dl); TG, plasma triglyceride levels 
(mg/dl); wk. week; %, phenotypic variance explained; B, B6 allele; T, TALLYHO allele; NS, not significant. 
 
 
Table 13. Significant QTLs in F2 mice from an intercross of F1(B6 x TH) mice (males). 
Phenotype values p value Marker (cM) Trait Wk % B/B H (B/T) T/T B vs H B vs T T vs H
Chr 1          
D1Mit215 (47) Ing 24 18 0.7±0.1(45) 1.0±0.1 1.1±0.1(40) 0.0057 <.0001 0.0360
 Epi 24 18.3 1.1±0.1(45) 1.4±0.1(80) 1.7±0.1(40) 0.0143 <.0001 0.0126
 Retro 24 16.6 0.3±0.02(44) 0.4±0.02(80) 0.5±0.03(40) 0.0090 <.0001 0.0428
 TF 24 17.3 2.8±0.2(45) 3.6±0.2(80) 4.2±0.2(40) 0.0026 <.0001 0.0339
 BF 24 17.9 0.17±0.01(44) 0.21±0.01(80) 0.24±0.01(40) 0.0027 <.0001 0.0312
D1Mit26(62.1) Mes 24 17.6 0.3±0.02(45) 0.4±0.02(80) 0.40±0.03(40) 0.0014 <.0001 NS 
D1Mit113 TG 20 16.3 152.8±8.1(44) 182.9±8.4(86) 226.7±15(35) 0.0311 <.0001 0.0040
(93.9) Chol 16 22.9 2.4±0.1(47) 2.7±0.1(88) 3.2±0.1(36) NS <.0001 0.0002
 Chol 20 19.2 2.8±0.2(44) 3.1±0.1(86) 4.0±0.2(35) NS <.0001 0.0001
 Ing 24 15.2 0.8±0.1(43) 0.9±0.1(82) 1.2±0.1(35) NS 0.0001 0.0052
 BF 24 14.2 0.2±0.01(43) 0.2±0.01(81) 0.3±0.03(35) NS 0.0004 0.0026
Chr 4          
D4Mit37(56.5) Glu 24 19.8 129.9±7.3(36) 167.2±4.2(101) 150.9±8.0(31) <.0001 0.0472 NS 
Chr 8          
D8Mit242(47) TG 24 18.8 156.3±8.1(44) 184.8±7.3(85) 221.0±12.4(37) 0.0207 <.0001 0.0057
Chr 10          
D10Mit11(50) Chol 16 15.2* 2.6±0.1(73) 3.0±0.1(43) 2.4±0.1(40) 0.0031 NS 0.0002
Data are presented as mean ± SE; Chr, chromosome; WT, weight (g); Chol, plasma cholesterol levels (mmol/l); Glu, plasma 
glucose levels (mg/dl); TG, plasma triglyceride levels (mg/dl); FFA, plasma free fatty acid levels (mmol/l); INS, plasma 
insulin levels (ng/ml); Ing, inguinal fat pad (g); Epi, epididymal fat pad (g);  Mes, mesenteric fat pad (g); Retro, 
retroperitonal (including perirenal) fat pad (g); BF, brown fat pad (g); TF, total fat pad (sum of inguinal, epididymal, 
mesenteric,  retroperitonal (including perirenal) and subscapular fat pad weights) (g); Carc, carcass weight (Body weight 
without the total fat pad) (g); wk. week; %, phenotypic variance explained; B, B6 allele; T, TALLYHO allele; NS, not 
significant. 
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the trait (Table 12).  At this marker, the mean plasma glucose levels in F2 mice 
homozygous for TH allele was significantly higher than that of mice homozygous for B6 
allele and heterozygous. The marker D4Mit37 also showed a linkage for plasma glucose 
levels at 24wk, accounting for 20% of the phenotypic variance of the trait (Table 13).  At 
this marker, the mean plasma glucose levels in F2 mice homozygous for TH allele was 
significantly higher than that of mice homozygous for B6, but not that of heterozygous 
mice (Table 13). 
 
QTLs controlling for plasma total cholesterol levels. 
A significant linkage for the plasma total cholesterol levels was detected at the 
marker D1Mit113 on chromosome 1, accounting for 22.9% and 19.2% of the phenotypic 
variance of the trait at 16 and 20 wk, respectively (Table 13).  Also, the marker D10Mit11 
showed a significant linkage for plasma cholesterol levels and accounted for 15.2% of 
phenotypic variance of the trait at 16 wk.  Even though TH is the susceptible strain, the 
heterozygotes showed significantly higher plasma cholesterol levels than mice 
homozygous for the TH allele at this locus (Table 13). 
 
QTLs controlling for various fat pads weights.  
At 24 wks of age, a significant linkage for fat pad weights was detected at marker 
D1Mit215 on chromosome 1, accounting for 11-18% of phenotypic variance of the trait 
(Table 13).  At this locus, F2 mice homozygous for TH allele had significantly higher fat 
pad weights than homozygous mice for B6 allele and heterozygous mice.  The marker 
D1Mit113 also shows a linkage for fat pad weights although the effect was smaller than 
 43
at D1Mit215.  This QTL explained 9.4-15.2% of phenotypic variance of the trait and 
mice homozygous for TH allele had significantly higher fat pad weights than 
homozygous mice for B6 allele and heterozygous mice (Table 13). 
 
4. Discussion 
Abnormal lipid metabolism, or dyslipidemia, often precedes the onset of diabetes 
in T2DM patients.  HTG is the most commonly observed form of dyslipidemia and 
appears to adversely influence insulin action, becoming a risk factor for the development 
of T2DM or T2DM complications (132).  
The TH mouse is a model of T2DM, exhibiting insulin resistance, 
hyperinsulinemia, hyperglycemia, obesity, and HTG.  Multiple QTLs associated with 
obesity and hyperglycemia in backcross male progeny obtained from a cross between 
F1(B6xTH) and TH mice were previously identified (97).  In this study, QTL analysis 
was conducted for plasma lipid levels including TG, cholesterol, and FFA in F2 male 
mice generated from an intercross of F1(B6xTH) mice.  Plasma glucose and insulin 
levels and fat pad and body weights were also included in this analysis.  All QTLs 
detected in this study are summarized in Tables 12-14.   
For HTG, two significant QTLs were identified on chromosomes 1 (at marker 
D1Mit113) and 8 (at marker D8Mit242).  QTLs linked to lipid and lipoprotein 
metabolism have been previously reported in the chromosome 1 region, and these include  
lipoprotein QTL 3 (Lprq3) found in NZB/BINJ x SM/J cross (133), triglycerides (Trglyd)
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Table 14. Suggestive QTLs in F2 mice from an intercross of F1(B6 x TH) mice (males). 
Phenotype p value Marker (cM) Trait Wk % B/B H (B/T) T/T B vs H B vs T T vs H
Chr 1          
D1Mit213 Epi 24 12.2 1.2±0.1(37) 1.3±0.1(87) 1.6±0.1(37) NS 0.001 0.005
(25.7) Mes 24 12 0.3±0.02(37) 0.4±0.02(87) 0.5±0.03(37) NS 0.0007 0.0184
 BF 24 10.5 0.2±0.01(36) 0.2±0.01(36) 0.2±0.01(37) NS 0.0015 0.0323
D1Mit215 Chol 16 10.5 2.5±0.1(50) 2.7±0.1(86) 3.0±0.1(40) NS 0.0013 0.283
(47) Subsc 24 11.8 0.3±0.03(45) 0.5±0.05(80) 0.6±0.03(40) 0.0049 0.0016 NS 
D1Mit26 Epi 24 10.1 1.2±0.1(42) 1.3±0.1(77) 1.6±0.1(44) NS 0.0034 0.0091
(62.1) BF 24 13.9 0.2±0.01(42) 0.2±0.01(76) 0.2±0.01(44) 0.0053 0.0003 NS 
D1Mit113 Glu 16 9.2 166.0±4.7(47) 160.0±3.5(88) 180.2±6.2(36) NS NS 0.0027
(93.9)  20 10.2 153.3±4.0(44) 157.4±3.1(86) 174.0±7.1(36) NS 0.0040 0.0087
 TG 16 8.7 141.4±8.6(47) 168.7±7.3(88) 185.0±14(36) 0.030 0.0049 NS 
  24 11.8 169.5±8.5(44) 180.9±7.1(84) 220.0±14(35) NS 0.0012 0.0045
 Chol 8 13.2 2.6±0.1(47) 3.2±0.1(88) 3.3±0.1(37) 0.0014 0.0017 NS 
  12 14.3 2.5±0.2(46) 3.2±0.1(88) 3.7±0.2(36) 0.0029 0.0001 NS 
 WT 16 10.8 33.8±0.6(47) 53.1±0.4(88) 36.7±0.8(36) NS 0.0011 0.0399
 Epi 24 9.4 1.3±0.1(43) 1.4±0.1(82) 1.6±0.1(35) NS 0.0035 0.0110
 Mes 24 10.1 0.3±0.02(42) 0.4±0.02(82) 0.5±0.03(35) NS 0.0017 NS 
 Retro 24 10.1 0.3±0.02(42) 0.4±0.02(82) 0.5±0.03(35) NS 0.0029 0.0076
 TF 24 9.4 3.1±0.2(43) 3.5±0.2(82) 4.3±0.3(35) NS 0.0007 0.0132
Chr 2          
D2Mit1(1) BF 24 10.4 0.20±0.01(32) 0.22±0.01(86) 0.17±0.01(46) NS NS 0.0015
D2Mit296 INS 16 11.1 2.7±0.4(33) 1.9±0.2(89) 2.4±0.4(46) NS NS NS 
(18) WT 8 10.2 28.8±0.41(33) 28.7±0.3(90) 30.2±0.5(47) NS 0.0272 0.0021
D2Mit56(41) Glu 16 9.6 176.6±5.6(39) 156.7±3.9(81) 166.5±4.2(44) 0.0026 NS NS 
D2Mit200 Glu 20 10.8 172.2±6.3(36) 153.5±3.4(78) 158.4±3.9(57) 0.0037 0.0408 NS 
(107) BF 24 10.5 0.24±0.02(36) 0.18±0.01(73) 0.21±0.01(55) 0.0018 NS NS 
Chr 4          
D4Mit97(6.3) TG 20 10.5 162.3±8.8(41) 174.5±7.9(85) 211.1±15.8(36) NS 0.0045 0.0142
D4Mit178(35.5) TG 20 17.5 148.9±89(36) 181.4±7.3(98) 219.7±16.3(36) 0.0282 <.0001 0.0099
D4Mit37 Glu 8 12.8 166.6±5.5(38) 190.1±3.5(108) 193.4±7.4(34) 0.001 0.0026 NS 
(56.5)  16 10.4 159.2±5.6(37) 161.4±3.2(105) 181.6±6.2(34) NS 0.0059 0.0028
  20 14.9 143.5±3.7(37) 160.8±3.3(102) 171.9±5.4(32) 0.0039 0.0002 NS 
 TG 24 9.3 176.3±11.(36) 179.2±6.5(101) 219.5±13.9(31) NS 0.0098 0.0042
D4Mit312(69.8) Glu 8 10.9 173.5±4.1(47) 186.3±4.0(95) 201.5±7.4(33) NS 0.0011 0.0456
D4Mit208(81.5) Glu 8 11.6 172.5±4.8(47) 188.2±4.3(91) 202.1±6.0(31) 0.0227 0.0009 NS 
Chr 8          
D8Mit339(23) TG  20 10.4 162.3±8.1(63) 188.8±10.5(58) 202.7±13.3(46) NS 0.008 NS 
D8Mit242(47) TG 20 13 152.0±6.8(44) 182.7±8.5(84) 212.4±15.8(38) 0.0314 0.0004 0.0471
Chr 10          
D10Mit130(31.5) Chol 12 10 2.6±0.2(53) 3.4±0.2(75) 3.3±0.2 (41) 0.0032 0.0188 NS 
D10Mit11 TG 20 12.6 167.2±7.7(70) 221.5±13.8(41) 164.1±13.2(39) 0.0004 NS 0.001
(50)  20 11.4 2.9±0.1(70) 3.7±0.2(41 3.2±0.2(39) 0.0005 NS 0.0457
  24 10.1 3.7±0.2(71) 2.9±0.2(41) 3.1±0.2(39 0.0033 0.0248 NS 
 FFA 20 11 1.4±0.1(70) 1.1±0.1(41) 1.1±0.1(39) 0.0019 0.0102 NS 
 INS 12 9.6 1.3±0.1(73) 2.1±0.3(43) 1.5±0.2(39) 0.0018 NS NS 
Chr 11          
D11Mit20 FFA 20 10.7 1.1±0.1(49) 1.3±0.1(71) 1.4±0.1(44) 0.0161 0.0029 NS 
(20) BF 24 10.8 0.2±0.01(45) 0.2±0.01(69 0.2±0.02(40) 0.0153 0.0018 NS 
D11Mit86 WT 16 9.8 33.5±0.6(49) 35.9±0.5(73) 35.2±0.6(48) 0.0021 0.0386 NS 
(28) WT 20 13.7 35.1±0.6(49) 38.1±0.5(71) 37.6±0.7(45) 0.0004 0.0073 NS 
 WT 24 14.8 35.8±0.7(48) 39.4±0.6(69) 38.6±0.8(45) 0.0002 0.0066 NS 
 Carc 24 15 31.2±0.5(48) 33.9±0.4(68) 33.3±0.6(45) 0.0002 0.006 NS 
 BF 24 13.7 0.17±0.01(48) 0.22±0.01(68) 0.23±0.02(44) 0.0017 0.0009 NS 
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Table 14. Continued. 
Phenotype p value Marker (cM) Trait Wk % B/B H (B/T) T/T B vs H B vs T T vs H
Chr 12          
D12Mit34 WT 8 9.7 30.1±0.4(48) 28.9±0.3(91) 28.4±0.4(36) 0.0138 0.0039 NS 
(29) WT 12 11.1 33.7±0.5(48) 32.4±0.4(91) 31.3±0.6(36) 0.0321 0.0011 0.0246
Chr 13          
D13Mit148(59) Chol 24 12.9 2.9±0.2(56) 3.7±0.2(77) 3.0±0.2(30 0.0012 NS 0.0246
Chr 15          
D15Mit2(46.9) Chol 16 10.7 2.8±0.1(36) 2.8±0.1(85) 2.4±0.1(49) NS 0.007 0.0032
Data are presented as mean ± SE; Chr, chromosome; WT, weight (g); Chol, plasma cholesterol levels (mmol/l); Glu, 
plasma glucose levels (mg/dl); TG, plasma triglyceride levels (mg/dl); FFA, plasma free fatty acid levels (mmol/l); INS, 
plasma insulin levels (ng/ml); Epi, epididymal fat pad (g);  Mes, mesenteric fat pad (g); Retro, retroperitonal fat pad (g); 
Subsc, subscapular fat pad (g); BF, brown fat pad (g); TF, total fat pad (sum of inguinal, epididymal, mesenteric,  
retroperitonal (including perirenal) and subscapular fat pad weights) (g); Carc, carcass weight (Body weight without the 
total fat pad); wk. week; %, phenotypic variance explained; B, B6 allele; T, TALLYHO allele ; NS, not significant. 
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in C57BL/6J x RR cross (81), cholesterol QTL 2 (Cq2) in CAST/Ei x 129S1/SvImJ cross 
(83), plasma cholesterol 1 (Pcho1) in (AKxD) x (129xSJL129F) cross (134), and fasting 
glucose 2 (Fglu2) in C57BL/6J x KK-A(y) cross mice (134) (Table 15).  Also, a QTL 
associated with plasma TG levels, Triglyceride level 1 (Tgl1), has been reported on 
chromosome 8 in BALB/c x KK/Ta cross (74) (Table 15).  Whether allelic variants at the 
TH associated HTG QTLs are responsible for the phenotypes linked to these QTLs 
remains to be determined.  
Apolipoprotein AII (Apoa2) gene isolated near the marker D1Mit113.  Apoa2 is a 
major constituent of human HDL (135).  Transgenic mice overexpressing Apoa2 gene 
exhibit several traits associated with T2DM, including glucose intolerance, insulin 
resistance, HTG, and obesity (136,137).  Furthermore, a number of nucleotide 
substitutions in Apoa2 cDNA has been reported in several inbred strains (138). Three 
different Apoa2 alleles, Apoa2a, Apoa2b, and Apoa2C, are known on the basis of amino  
acid substitutions at four residues (135).  Analysis with Apoa2 congenic strains revealed 
that the Apoa2b allele is unique for increased cholesterol among the three Apoa2 alleles, 
and that the Ala-to-Val substitution at residue 61 may be crucial as far as cholesterol 
metabolism is concerned (81).  In humans, Apoa2 is located in chromosome 1q23, a 
region that is associated with combined hyperlipidemia, insulin resistance and T2DM 
(139).  These studies suggest the Apoa2 gene as a logical candidate for the HTG QTL on 
chromosome 1 that remains to be tested. 
For plasma glucose levels, we identified a QTL on chromosome 4, that accounted 
for 23 % of the phenotypic variance (Table 12).  Although there was no evidence of 
linkage for this QTL to obesity in our study, several QTLs associated with obesity have 
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Table 15. Summary of significant QTLs. 
Marker (cM) Real peak (cM) Trait Overlapping QTL (cM) (ref.) 
D1Mit213 (26) 25.76 Epi, Mes, BF Tgq2 (30) (124) 
D1Mit215 (47) 47.12 Chol, Ing, Epi, Retro, Subsc, BF Bw5 (36) (142) Bwtq1 (54.3) (143) 
D1Mit26 (62) 62.61 Epi, Mes, BF 
Fatq1 (62) (140) 
Obwq1 (62) (140) 
Opq8 (69.1) (140,144) 
D1Mit113 (93) 94.51 Glu, TG, Chol, WT, Ing, Epi, Retro, Subsc, BF Lprq3 (92) (133) 
D1Mit206 (96) 94.53 Glu, TG, Chol, WT, Ing, Epi, Mes,TF, BF 
Hdlq20 (96) (145) 
Trglyd (95.8) (81) 
Cq2 (100) (82) 
Pcho1 (100) (79) 
Fglu2 (100) (134) 
D2Mit1 (1) 1 BF Adip10 (2) (140) 
D2Mit296 (18) 18.26 INS, WT Bodw1 (18) (93) 
D2Mit56 (41) 41.13 Glu Nidd5 (34.5) (141) 
D2Mit200 (107) 107 Glu, BF Bwq5 (81.7) (140,146) Bglu1 (87) (89) 
D4Mit97 (6.3) 6.44 TG Bwq1 (6.3) (140) Triglq1 (6.5) (94) 
D4Mit178 (36) 35.76 Glu, TG Bwq9 (24) (140) 
D4Mit37 (57) 57.14 Glu, TG 
Mob6, 7(49.6) (141) 
Bwtq2 (55) (142) 
Nidds (55) (147) 
Bw7 (59) (142) 
Tgq3 (58) (75) 
D4Mit312 (70) 70.60 Glu 
Afw2 (66) (95,140) 
Afpq2 (66) (95,140) 
Tafat (69.8) (97) 
Adip12 (70) (140) 
Dob1 (70) (140,148) 
D4Mit208 (82) 81.5 Glu  
D8Mit339 (23) 23.35 TG Trigq2 (30) (124) 
D8Mit242 (47) 47 TG Obq16 (48) (75) Tgl1 (51.5) (74) 
D10Mit130 (32) 31.92 Chol Scfpq1 (33) (140,149) 
D10Mit11 (50) 50 TG, Chol, FFA, INS Igf1sl2 (51) (150) Adip15 (52) (140) 
D11Mit20 (20) 20.12 FFA, BF Bw16 (14) (151) 
D11Mit86 (28) 28.25 WT, Carc, BF Bwtq5 (27.8) (142) 
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Table 15. Continued. 
Marker (cM) Real peak (cM) Trait Overlapping QTL (cM) (ref.) 
D12Mit34 (29) 29.18 WT 
Afpq10 (18) (84,140) 
Fob2 (19) (140,152) 
Afw10 (21) (84,140) 
Adip16 (26) (140) 
D13Mit148 (59) 59.91 Chol Tanidd2 (60) (97) 
D15Mit2 (47) 46.9 Chol Bwtq12 (34) (140) 
cM, centimorgan; ref, reference; Tgq2, triglyceride QTL 2; Bw5, body weight QTL 5; Bwtq1, body 
weight QTL 1;Fatq1, percent fat, subcutaneous and gonadal, QTL 1; Obwq1, obesity and body weight 
QTL 1; Obq8, obesity QTL 8; Lprq3, lipoprotein QTL 3; Hdlq20, HDL QTL 20; Trglyd, triglycerides; 
Cq2, cholesterol QTL 2; Pcho1, plasma cholesterol 1; Fglu2, fasting glucose 2; Adip10, adiposity 10; 
Bwtq8, body weight QTL 8; Bodw1, body weight 1; Nidd5, non-insulin-dependent diabetes mellitus 5; 
Bwq5, body weight, QTL 5; Bglu1, blood glucose level 1; Bwq1, body weight QTL 1; Triglq1, 
triglyceride QTL 1; Bwq9, body weight, QTL 9; Mob6, multigenic obesity 6; Bwtq2, body weight QTL 2; 
Nidds, non-insulin-dependent diabetes mellitus in SJL; Bw7, body weight QTL 7; Tgq3, triglyceride QTL 
3; Afw2, abdominal fat weight QTL 2; Afpq2, abdominal fat percent QTL 2; Tafat, TallyHo associated fat; 
Adip12, adiposity 12; Dob1, dietary obesity 1; Trigq2, triglyceride QTL 2; Obq16, obesity QTL 16; Tgl1, 
triglyceride level 1; Scfpq1, subcutaneous fat pad percentage QTL 1; Igf1sl2, IGF-1 serum levels 2; 
Adip15, adiposity 12; Bw16, body weight QTL 16; Bwtq5, body weight QTL 5; Afpq10, abdominal fat 
percent QTL 10; Fob2, F-line obesity QTL 2, Afw10, abdominal fat weight QTL 10; Adip16, adiposity 
16; Tanidd2, TallyHo associated non-insulin dependent diabetes mellitus 2; Bwtq12, body weight QTL 12, 
Chol, Plasma Cholesterol; Glu, Plasma Glucose; TG, Plasma Triglyceride; INS, Plasma Insulin; FFA, 
Plasma Free Fatty Acid; Ing, Inguinal fat pad, Epi, Epididymal fat pad; Mes, Mesenteric fat pad; Retro, 
Retroperitonal fat pad; BF, Brown fat pad; TF, Total fat pad [sum of inguinal, epididymal, mesenteric,  
retroperitonal (including perirenal) and subscapular fat pad weights]; Subsc, Subscapular fat pad; Carc, 
Carcass weight (Body weight without the total fat pad) ; WT, Body weight. 
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been detected in this region.  These include body weight QTL 9 (Bwq9, 24 cM) found in 
SM/J x NZB/BINJ cross (140), multigenic obesity 6 (Mob6, 49.6 cM) in SM/J x A/J 
cross (141), body weight QTL 2 (Bwtq2, 55 cM) in A/a x Avy/A cross (142), and body 
weight 7 (Bw7, 59 cM) in A/a x Avy/A cross (142).  Also, QTLs associated with diabetes 
and lipid metabolism including non-insulin-dependent diabetes (Nidds, 55 cM) and 
triglyceride QTL 3 (Tgq3, 58 cM) have been detected in NZO x SJL cross and B6 x 
129/SvImJ cross, respectively. 
A major QTL linked to fat pad weights was detected on chromosome 1, proximal 
to the HTG QTL (Table 13).  Several QTLs associated with obesity have been previously 
reported in this region, including body weight QTL 5 (Bw5, 36 cM) in A/a x Avy/A cross 
(142), obesity QTL 16 (Obq16, 48 cM) in C57BL/6J x 129S1/SvImJ cross (75), body 
weight QTL 1 (Bwtq1, 54.3 cM) in B6 x DBA/2J cross (143), percent fat, subcutaneous 
and gonadal, QTL 1 (Fatq1, 62 cM) in SM/J x NZB/BINJ cross, obesity and body weight 
QTL 1 (Obwq1) in SM/J x NZB/BINJ cross, and obesity QTL 8 (Obq8) in SM/J x 
NZB/BINJ cross (140). A QTL linked to plasma TG levels, triglyceride level 1 (Tgl1, 
51.5 cM), was also reported in this region in BALB/c x KK/Ta cross (74).  
 Previously reported QTLs that overlap with significant and suggestive QTLs 
detected in our study are summarized in Table 15.  
 In conclusion, this study reveals complex inheritance associated with diabetes, 
obesity and dyslipidemia and identifies significant QTLs contributing to the development 
of these metabolic abnormalities in TH mice. 
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Chapter IV: Conclusions and Future Directions 
 
 Diabetes is a disorder characterized by alterations in carbohydrate and lipid 
metabolism.  HTG is the dominant feature of dyslipidemia observed in T2DM patients.  It 
is well-recognized that genetic factors significantly influence the development of HTG, 
yet no susceptibility genes for common forms of HTG have been identified in humans to 
date.  In the present study, we have found significant QTLs contributing to HTG, obesity 
and diabetes in TH mice.  
Our ultimate goal includes identifying the molecular bases of these QTLs.  One 
plausible approach by which this goal can be accomplished is conducting expression 
QTL (eQTL) analysis using the F2 progeny.  The diversity in gene expression is one of 
the mechanisms for diversity among individuals, such as susceptibility to disease.  A 
differential gene expression could be due to a cis-acting polymorphism at the gene itself 
(153,154), or due to a polymorphism of a gene upstream. Therefore, analysis of 
determinants of differential gene expression is important not only to study the 
architecture of transcriptional regulation, but also to identify causative genes for various 
diseases.  However, it is often difficult to determine whether differential gene expression 
is a cause or consequence, in other words, whether it is due to a cis-acting or trans-acting 
polymorphism (155).  A new approach to this issue is to treat mRNA expression levels as 
quantitative traits, and to map QTLs that control the expression levels in vivo.  Using 
cDNA microarray technology, several studies performed comprehensive analysis of 
mRNA expression and QTLs controlling the expression in budding yeast (156), 
eucalyptus (157), mice (158), rats (159), and humans (158,160-162).  The studies 
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indicated that this approach, eQTL analysis, is effective for identification of the cause of 
the expression differences in vivo, and can be applied to various genes.   
Quantitative gene expression profiling of liver, adipose, tissue, skeletal muscle, 
and pancreas can be carried out in the F2 mice from this study by linkage QTL mapping 
analysis, treating the levels of gene expression as quantitative traits.  To search for 
candidate gene(s) QTLs, linked to the levels of gene expression can then be examined for 
overlap with QTLs linked to HTG found in this study.  If gene(s) showing transcriptional 
variation maps to the QTL region for HTG, this gene(s) becomes a strong candidate gene 
based on the idea that the susceptibility gene(s) responsible for the HTG acts in cis.  
Otherwise, candidates will be searched among the transcriptional regulatory genes. 
We can also narrow the genomic intervals (fine mapping) of the QTLs and 
pursue positional cloning to identify the actual allelic variants (molecular basis).  The 
first step for this experiment is the development of congenic strains in which the 
individual QTL is separated as new inbred strain on a common genetic background such 
as B6 strain (163).  In this simpler system, we can apply conventional genetic mapping 
and positional cloning methods for identification of each QTL.  This strategy has proven 
to be highly successful in fine mapping the type 1 diabetes susceptibility genes including 
Idd3, and interleukin-2 is strongly demonstrated as a candidate gene for Idd3 within the 
interval (164).  Also, using congenic strain, Clee et al. have recently identified Sorcs 1 
gene for the QTL of type 2 diabetes mellitus-2 locus (T2dm2) affecting fasting insulin 
levels in a leptin-deficient obese F2 mice derived from B6 and BTBR T+tf/J (BTBR) 
mice (165).  
Once genes responsible for HTG and diabetes are identified in mice, they can 
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serve as crucial candidates for humans.  Therefore, the present study is important to 
establish a framework of mapping QTLs for candidate gene(s) and pathway(s) for the 
susceptibility to the HTG and diabetes in TH mice.  This information can contribute to 
identifying targets for lipid lowering therapy and ultimately to manage and prevent 
diabetes and CHD in T2DM patients.  
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